Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
APEX: TX000045 in PH-HFpEF
NCT06616974Phase 2Active, not recruiting
- Sponsor
- Tectonic Therapeutic
- Start
- Sep 2024
- Primary completion
- Nov 2026
- Modality
- Antibody Fragments, Fc-Fusion Proteins
- Countries
- 17
01
Overview
Phase 2, randomised, double-blind trial of TX000045 in pulmonary hypertension (PH) and heart failure with preserved ejection fraction (HFpEF) (3 arms), sponsored by Tectonic Therapeutic. Primary endpoints: Pulmonary Vascular Resistance at 24 weeks, Adverse Events at 30 weeks and 3 more. Started Sep 2024; status: active, not recruiting.
02
Drugs
TX000045
03
Conditions
pulmonary hypertension (PH)heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on NCT06616974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06616974.